ClinicalTrials.gg
RecruitingNCT07384143CROSS-NDUpdated Feb 3, 2026

Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders

An interventional study of Sensor-Based Robotic Rehabilitation with Cognitive Tasks (SBRR) and Standard Conventional Therapy in PARKINSON DISEASE (Disorder), Multiple Sclerosis and Stroke, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2025, registered Sep 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo — 6 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · IRCCS Centro Neurolesi Bonino Pulejo.

Planned enrollment
4th of 13
189 · median 60
Started
2025
with 3 others
No phase
13 of 13
6 open now
Registered
11th of 13
by date

Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, this one is the 4th largest by planned enrollment, is one of 4 that started in 2025, is one of 13 with no phase, and was the 11th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if sensor-based robotic upper limb rehabilitation can improve cognitive and motor functions in adults with neurological and neurodegenerative disorders, including Parkinson's disease, multiple sclerosis, and stroke. The main questions it aims to answer are:

Does sensor-based robotic rehabilitation improve cognitive functions such as attention, memory, and executive functions? Does this rehabilitation lead to better motor recovery and daily functioning compared to conventional therapy? Researchers will compare the experimental group receiving robotic rehabilitation with cognitive tasks to the control group receiving conventional therapy to see if the robotic approach leads to greater improvements in both cognitive and motor outcomes.

Participants will:

Receive upper limb rehabilitation using robotic devices and virtual reality-based exercises or conventional therapy Complete a series of neuropsychological assessments before and after the intervention to measure cognitive changes Complete motor function tests before and after the intervention to evaluate physical improvements Participate in 25 training sessions, 2-3 times per week, each lasting 60 minutes

Read the detailed description

The CROSS-ND study is a randomized controlled trial designed to evaluate the effectiveness of sensor-based robotic upper limb rehabilitation combined with cognitive exercises in adults with neurological and neurodegenerative disorders, including Parkinson's disease, multiple sclerosis, and stroke. Traditional rehabilitation often focuses primarily on motor recovery, but cognitive impairments frequently co-occur and can limit functional gains. This study integrates cognitive tasks within robotic rehabilitation to target both motor and cognitive deficits simultaneously, promoting neuroplasticity and functional independence.

Participants will be randomly assigned to either the experimental group, receiving robotic and virtual reality-based upper limb training with embedded cognitive exercises, or the control group, receiving conventional therapy. Each participant will complete 25 sessions over 2-3 months, with training intensity and difficulty adapted to individual performance.

Assessments will include neuropsychological tests tailored to the patient's condition (ACE-R for Parkinson's, BRB-N for multiple sclerosis, RBANS for stroke) and motor evaluations using standardized tools such as Fugl-Meyer Assessment, Nine Hole Peg Test, and robotic device metrics. Cognitive and motor outcomes will be measured at baseline (T0) and immediately post-intervention (T1).

This study aims to demonstrate that a personalized, integrated rehabilitation approach can improve cognitive functions (attention, memory, executive functions, visuospatial skills) while enhancing motor recovery and daily living activities. Secondary objectives include analyzing correlations between cognitive and motor improvements, evaluating psychological well-being, and exploring the influence of patient characteristics (age, severity, disease stage) on rehabilitation outcomes.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)
  • Multiple Sclerosis
  • Stroke
  • Neurological Disorders
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years;
  • FMA-UL 0-31: eligible for exoskeletons and robotic devices with high support. (Armeo Power, Amadeo, Motore)
  • FMA-UL 32-47: eligible for end-effectors with medium support. (Armeo Spring, Hand Tutor, Diego)
  • FMA-UL 48-52: eligible for sensor-based with low support. (Pablo, Diego, Armeo Senso)
  • : ≤ 20

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive disorders
  • Behavioral disorders
  • Sensory disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
189 participants (estimated)

Study arms

  • Experimental
    Sensor-Based Robotic Rehabilitation with Cognitive Tasks (SBRR)

    Participants receive upper limb rehabilitation using sensor-based robotic devices and virtual reality exercises, with integrated cognitive tasks to simultaneously improve motor function and cognitive abilities.

    Device: Sensor-Based Robotic Rehabilitation with Cognitive Tasks (SBRR)

  • Active comparator
    Standard Conventional Therapy (SCT)

    Participants receive conventional upper limb rehabilitation, including standard physiotherapy exercises, without robotic assistance or integrated cognitive tasks.

    Device: Standard Conventional Therapy

Interventions

  • DeviceSensor-Based Robotic Rehabilitation with Cognitive Tasks (SBRR)

    Participants receive upper limb rehabilitation using sensor-based robotic devices (e.g., Motore, Armeo Senso, Hand Tutor, Armeo Power, Armeo Spring, Pablo, Amadeo, Diego) combined with virtual reality exercises. The intervention integrates cognitive tasks-such as attention, memory, and executive function exercises-simultaneously with motor training. Therapy is personalized in real-time according to each patient's performance, adjusting difficulty, intensity, and assistance levels to maximize both cognitive and motor recovery.

  • DeviceStandard Conventional Therapy

    Participants receive traditional upper limb rehabilitation, including standard physiotherapy exercises without robotic assistance or integrated cognitive tasks. Therapy focuses on motor recovery using conventional methods, such as repetitive movement exercises, range of motion, and functional tasks, but does not adapt in real-time to patient performance and does not include concurrent cognitive stimulation.

06

What researchers measure

Primary outcomes

  1. Between-group difference in change from baseline in Addenbrooke's Cognitive Examination-Revised (ACE-R) total score (Parkinson's disease)

    Addenbrooke's Cognitive Examination-Revised (ACE-R) total score ranges from 0 to 100, with higher scores indicating better cognitive performance. ACE-R will be administered at baseline (T0) and at end of intervention (T1). The primary metric will be change from baseline (T1 - T0) in ACE-R total score. Results will be summarized as mean (SD) change (or median \[IQR\] if non-normal) and compared between robotic rehabilitation and conventional therapy groups.

    Time frame: From baseline (Visit 1) to end of treatment (Visit 2; after completion of 25 rehabilitation sessions; 2-3 sessions/week; each session 60 minutes; total duration ~8-12 weeks).

  2. Between-group difference in change from baseline in Brief Repeatable Neuropsychological Test (BRNT) composite score (Multiple Sclerosis)

    The BRB-N is a neuropsychological battery (multiple subtests). Subtest scores will be standardized into z-scores and aggregated into a composite (e.g., mean z-score across predefined subtests). Z-scores have no fixed minimum or maximum; higher values indicate better cognitive performance.The BRNT will be administered at T0 and T1. The primary metric will be change from baseline (T1 - T0) in a composite score derived from BRNT components (standardized z-scores aggregated into a single composite). Results will be summarized as mean (SD) change and compared between groups.

    Time frame: From baseline (Visit 1) to end of treatment (Visit 2; after completion of 25 rehabilitation sessions; 2-3 sessions/week; each session 60 minutes; total duration ~8-12 weeks).

  3. Between-group difference in change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index score (Stroke)

    RBANS Total Scale Index score ranges from 40 to 160, with higher scores indicating better cognitive performance. RBANS will be administered at T0 and T1. The primary metric will be change from baseline (T1 - T0) in RBANS Total Scale Index score. Results will be summarized as mean (SD) change (or median \[IQR\]) and compared between robotic rehabilitation and conventional therapy groups.

    Time frame: From baseline (Visit 1) to end of treatment (Visit 2; after completion of 25 rehabilitation sessions; 2-3 sessions/week; each session 60 minutes; total duration ~8-12 weeks).

Secondary outcomes

  1. Between-group difference in change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE/FMA-UL) score

    FMA-UE score ranges from 0 to 66, with higher scores indicating better upper-limb motor function. FMA-UL will be assessed at T0 and T1. Metric: change from baseline (T1 - T0). Summaries: mean (SD) change and between-group comparison.

    Time frame: From baseline (T0) to immediately after the final rehabilitation session (T1; after completion of 25 sessions; 2-3 sessions/week; 60 minutes/session; total duration ~8-12 weeks).

  2. System Usability Scale (SUS) score for robotic device usability at end of treatment

    SUS total score ranges from 0 to 100, with higher scores indicating better usability. Participants will complete the SUS at T1 to evaluate usability of the robotic device. Metric: SUS total score. Summaries: mean (SD) (or median \[IQR\]).

    Time frame: From baseline (T0) to immediately after the final rehabilitation session (T1; after completion of 25 sessions; 2-3 sessions/week; 60 minutes/session; total duration ~8-12 weeks).

  3. Goal Attainment Scaling (GAS) T-score at end of treatment

    GAS is calculated as a standardized T-score typically centered at 50 (SD 10); scores \>50 indicate better-than-expected goal attainment, while scores \<50 indicate less-than-expected attainment. Individualized rehabilitation goals will be defined at baseline and evaluated at T1 using GAS. Metric: GAS T-score at T1 (or change, se lo calcoli). Summaries: mean (SD) and between-group comparison.

    Time frame: From baseline (T0) to immediately after the final rehabilitation session (T1; after completion of 25 sessions; 2-3 sessions/week; 60 minutes/session; total duration ~8-12 weeks).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bard-Pondarre R, Villepinte C, Roumenoff F, Lebrault H, Bonnyaud C, Pradeau C, Bensmail D, Isner-Horobeti ME, Krasny-Pacini A. Goal Attainment Scaling in rehabilitation: An educational review providing a comprehensive didactical tool box for implementing Goal Attainment Scaling. J Rehabil Med. 2023 Jun 14;55:jrm6498. doi: 10.2340/jrm.v55.6498. PubMed 37317629 ↗
  • Moulaei K, Moulaei R, Bahaadinbeigy K. The most used questionnaires for evaluating the usability of robots and smart wearables: A scoping review. Digit Health. 2024 Apr 9;10:20552076241237384. doi: 10.1177/20552076241237384. eCollection 2024 Jan-Dec. PubMed 38601185 ↗
  • Bull R, Espy KA, Senn TE. A comparison of performance on the Towers of London and Hanoi in young children. J Child Psychol Psychiatry. 2004 May;45(4):743-54. doi: 10.1111/j.1469-7610.2004.00268.x. PubMed 15056306 ↗
  • Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9. doi: 10.1076/jcen.20.3.310.823. PubMed 9845158 ↗
  • Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, Barbieri E, Baldini S, Salmaggi A, Mantia LL, Farinotti M, Caputo D, Mosconi P. Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):158-62. doi: 10.1136/jnnp.67.2.158. PubMed 10406981 ↗
  • Tedone N, Vizzino C, Meani A, Gallo A, Altieri M, D'Ambrosio A, Pantano P, Piervincenzi C, Tommasin S, De Stefano N, Cortese R, Stromillo ML, Rocca MA; INNI network; Filippi M. The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI). J Neurol. 2024 Apr;271(4):1813-1823. doi: 10.1007/s00415-023-12108-z. Epub 2023 Dec 7. PubMed 38060030 ↗
  • Galeoto G, Colalelli F, Massai P, Berardi A, Tofani M, Pierantozzi M, Servadio A, Fabbrini A, Fabbrini G. Quality of life in Parkinson's disease: Italian validation of the Parkinson's Disease Questionnaire (PDQ-39-IT). Neurol Sci. 2018 Nov;39(11):1903-1909. doi: 10.1007/s10072-018-3524-x. Epub 2018 Aug 7. PubMed 30088166 ↗
  • Nocentini U, Giordano A, Di Vincenzo S, Panella M, Pasqualetti P. The Symbol Digit Modalities Test - Oral version: Italian normative data. Funct Neurol. 2006 Apr-Jun;21(2):93-6. PubMed 16796824 ↗
  • Siciliano M, Chiorri C, Battini V, Sant'Elia V, Altieri M, Trojano L, Santangelo G. Regression-based normative data and equivalent scores for Trail Making Test (TMT): an updated Italian normative study. Neurol Sci. 2019 Mar;40(3):469-477. doi: 10.1007/s10072-018-3673-y. Epub 2018 Dec 7. PubMed 30535956 ↗
  • Siciliano M, Raimo S, Tufano D, Basile G, Grossi D, Santangelo F, Trojano L, Santangelo G. The Addenbrooke's Cognitive Examination Revised (ACE-R) and its sub-scores: normative values in an Italian population sample. Neurol Sci. 2016 Mar;37(3):385-92. doi: 10.1007/s10072-015-2410-z. Epub 2015 Nov 12. PubMed 26563847 ↗
  • Hoonhorst MH, Nijland RH, van den Berg JS, Emmelot CH, Kollen BJ, Kwakkel G. How Do Fugl-Meyer Arm Motor Scores Relate to Dexterity According to the Action Research Arm Test at 6 Months Poststroke? Arch Phys Med Rehabil. 2015 Oct;96(10):1845-9. doi: 10.1016/j.apmr.2015.06.009. Epub 2015 Jul 2. PubMed 26143054 ↗
  • Li, X., Tang, Z., Wu, D., Su, L., Zheng, Y., Chen, P., Zhang, Y., Dou, Z., Li, K., & Hoseinbeyki, A. (2021). Analysis of the Positive Effect of Robot-Assisted Virtual Reality Technology on Rehabilitation of Motor Function and Nerve Function in Cerebral Stroke Patients. J. Medical Imaging Health Informatics, 11, 595-600. https://doi.org/10.1166/jmihi.2021.3372.
  • Manuli A, Maggio MG, Latella D, Cannavo A, Balletta T, De Luca R, Naro A, Calabro RS. Can robotic gait rehabilitation plus Virtual Reality affect cognitive and behavioural outcomes in patients with chronic stroke? A randomized controlled trial involving three different protocols. J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104994. doi: 10.1016/j.jstrokecerebrovasdis.2020.104994. Epub 2020 Jun 13. PubMed 32689601 ↗
  • Metzger JC, Lambercy O, Califfi A, Conti FM, Gassert R. Neurocognitive robot-assisted therapy of hand function. IEEE Trans Haptics. 2014 Apr-Jun;7(2):140-9. doi: 10.1109/TOH.2013.72. PubMed 24968378 ↗
  • Calabro RS, Naro A, Russo M, Bramanti P, Carioti L, Balletta T, Buda A, Manuli A, Filoni S, Bramanti A. Shaping neuroplasticity by using powered exoskeletons in patients with stroke: a randomized clinical trial. J Neuroeng Rehabil. 2018 Apr 25;15(1):35. doi: 10.1186/s12984-018-0377-8. PubMed 29695280 ↗
  • Kiper P, Richard M, Stefanutti F, Pierson-Poinsignon R, Cacciante L, Perin C, Mazzucchelli M, Vigano B, Meroni R. Combined Motor and Cognitive Rehabilitation: The Impact on Motor Performance in Patients with Mild Cognitive Impairment. Systematic Review and Meta-Analysis. J Pers Med. 2022 Feb 14;12(2):276. doi: 10.3390/jpm12020276. PubMed 35207764 ↗
  • Riener R, Lunenburger L, Colombo G. Human-centered robotics applied to gait training and assessment. J Rehabil Res Dev. 2006 Aug-Sep;43(5):679-94. doi: 10.1682/jrrd.2005.02.0046. PubMed 17123208 ↗
  • Aprile I, Guardati G, Cipollini V, Papadopoulou D, Monteleone S, Redolfi A, Garattini R, Sacella G, Noro F, Galeri S, Carrozza MC, Germanotta M. Influence of Cognitive Impairment on the Recovery of Subjects with Subacute Stroke Undergoing Upper Limb Robotic Rehabilitation. Brain Sci. 2021 Apr 30;11(5):587. doi: 10.3390/brainsci11050587. PubMed 33946452 ↗
  • Aprile I, Guardati G, Cipollini V, Papadopoulou D, Mastrorosa A, Castelli L, Monteleone S, Redolfi A, Galeri S, Germanotta M. Robotic Rehabilitation: An Opportunity to Improve Cognitive Functions in Subjects With Stroke. An Explorative Study. Front Neurol. 2020 Nov 19;11:588285. doi: 10.3389/fneur.2020.588285. eCollection 2020. PubMed 33329334 ↗
  • Mehrholz J, Pollock A, Pohl M, Kugler J, Elsner B. Systematic review with network meta-analysis of randomized controlled trials of robotic-assisted arm training for improving activities of daily living and upper limb function after stroke. J Neuroeng Rehabil. 2020 Jun 30;17(1):83. doi: 10.1186/s12984-020-00715-0. PubMed 32605587 ↗
  • Xie H, Li X, Huang W, Yin J, Luo C, Li Z, Dou Z. Effects of robot-assisted task-oriented upper limb motor training on neuroplasticity in stroke patients with different degrees of motor dysfunction: A neuroimaging motor evaluation index. Front Neurosci. 2022 Sep 16;16:957972. doi: 10.3389/fnins.2022.957972. eCollection 2022. PubMed 36188465 ↗
  • Calabro RS, Morone G, Naro A, Gandolfi M, Liotti V, D'aurizio C, Straudi S, Focacci A, Pournajaf S, Aprile I, Filoni S, Zanetti C, Leo MR, Tedesco L, Spina V, Chisari C, Taveggia G, Mazzoleni S, Smania N, Paolucci S, Franceschini M, Bonaiuti D. Robot-Assisted Training for Upper Limb in Stroke (ROBOTAS): An Observational, Multicenter Study to Identify Determinants of Efficacy. J Clin Med. 2021 Nov 11;10(22):5245. doi: 10.3390/jcm10225245. PubMed 34830527 ↗
  • Germanotta M, Cortellini L, Insalaco S, Aprile I. Effects of Upper Limb Robot-Assisted Rehabilitation Compared with Conventional Therapy in Patients with Stroke: Preliminary Results on a Daily Task Assessed Using Motion Analysis. Sensors (Basel). 2023 Mar 13;23(6):3089. doi: 10.3390/s23063089. PubMed 36991799 ↗
  • Zengin-Metli D, Ozbudak-Demir S, Eraktas I, Binay-Safer V, Ekiz T. Effects of robot assistive upper extremity rehabilitation on motor and cognitive recovery, the quality of life, and activities of daily living in stroke patients. J Back Musculoskelet Rehabil. 2018;31(6):1059-1064. doi: 10.3233/BMR-171015. PubMed 29966188 ↗
  • Adomaviciene A, Daunoraviciene K, Kubilius R, Varzaityte L, Raistenskis J. Influence of New Technologies on Post-Stroke Rehabilitation: A Comparison of Armeo Spring to the Kinect System. Medicina (Kaunas). 2019 Apr 9;55(4):98. doi: 10.3390/medicina55040098. PubMed 30970655 ↗
  • Bui KD, Johnson MJ. Robot-Based Measures of Upper Limb Cognitive-Motor Interference Across the HIV-Stroke Spectrum. IEEE Int Conf Rehabil Robot. 2019 Jun;2019:530-535. doi: 10.1109/ICORR.2019.8779418. PubMed 31374684 ↗
  • Chen C, Leys D, Esquenazi A. The interaction between neuropsychological and motor deficits in patients after stroke. Neurology. 2013 Jan 15;80(3 Suppl 2):S27-34. doi: 10.1212/WNL.0b013e3182762569. PubMed 23319483 ↗
  • Lamb F, Anderson J, Saling M, Dewey H. Predictors of subjective cognitive complaint in postacute older adult stroke patients. Arch Phys Med Rehabil. 2013 Sep;94(9):1747-52. doi: 10.1016/j.apmr.2013.02.026. Epub 2013 Mar 22. PubMed 23529143 ↗
  • Pollock A, Farmer SE, Brady MC, Langhorne P, Mead GE, Mehrholz J, van Wijck F. Interventions for improving upper limb function after stroke. Cochrane Database Syst Rev. 2014 Nov 12;2014(11):CD010820. doi: 10.1002/14651858.CD010820.pub2. PubMed 25387001 ↗
  • Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009 Nov;8(11):1006-18. doi: 10.1016/S1474-4422(09)70236-4. Epub 2009 Sep 24. PubMed 19782001 ↗
  • Gottesman RF, Hillis AE. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke. Lancet Neurol. 2010 Sep;9(9):895-905. doi: 10.1016/S1474-4422(10)70164-2. PubMed 20723846 ↗
  • Lesniak M, Bak T, Czepiel W, Seniow J, Czlonkowska A. Frequency and prognostic value of cognitive disorders in stroke patients. Dement Geriatr Cogn Disord. 2008;26(4):356-63. doi: 10.1159/000162262. Epub 2008 Oct 14. PubMed 18852488 ↗
  • Nys GM, van Zandvoort MJ, de Kort PL, van der Worp HB, Jansen BP, Algra A, de Haan EH, Kappelle LJ. The prognostic value of domain-specific cognitive abilities in acute first-ever stroke. Neurology. 2005 Mar 8;64(5):821-7. doi: 10.1212/01.WNL.0000152984.28420.5A. PubMed 15753416 ↗
  • Loetscher T, Potter KJ, Wong D, das Nair R. Cognitive rehabilitation for attention deficits following stroke. Cochrane Database Syst Rev. 2019 Nov 10;2019(11):CD002842. doi: 10.1002/14651858.CD002842.pub3. PubMed 31706263 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2030, 60 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 60 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Feb 3, 2026
StartActual
Feb 11, 2025
Primary completionEst.
Feb 11, 2030
CompletionEst.
Feb 11, 2030
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07384143
Lead sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Responsible party
Desiree La Tella (Principal Investigator, IRCCS Centro Neurolesi Bonino Pulejo) — Principal investigator
First posted
Feb 3, 2026
Start date
Feb 11, 2025
Primary completion
Feb 11, 2030 (estimated)
Completion
Feb 11, 2030 (estimated)
Last update
Feb 3, 2026

Study contacts

Désirée Latella
Contact
desiree.latella@ircssme.it
+393458747117

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion